Diabetes Mellitus, Type 1
Conditions
Keywords
type 1diabetes, gaba
Brief summary
GABA(gamma-Aminobutyric acid) may be used for decreasing anti-gad antibodies and leads beta-cell regeneration.
Detailed description
100 patients with type I diabetes were in 2 groups, had been monitored in a private clinic, number 50 each group, with 30 females and 20 males after the written consent of all patients. All the patients Lied between 18-25 years old with 5-10 years of diabetes onset. The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day. The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily. In the first group;the investigator measured fasting c peptide levels before and after 6 months of GABA 750mg daily.Also,the investigator measured anti gad antibodies before and after 6 months of treatment. In the second group,the investigator measured c peptide levels and anti-gad antibodies at the beginning of the trial and after 6 months.
Interventions
DRUGGABA
GABA nutritional supplement 750mg per day for 6 months
Sponsors
Ministry of Health and Population, Egypt
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 25 Years
Inclusion criteria
\- type 1 diabetes patients age from 18 to 25 years on basal bolus insulin
Exclusion criteria
thyroid problems liver disease kidney disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| gaba decrease anti gad antibodies | 6 months | gaba 750 mg daily for type 1 diabetes patients |
| gaba improve c peptide levels | 6 months | gaba 750 mg pe day for type 1 diabetes patients |
Countries
Egypt
Outcome results
None listed